Key result
Ventricular dysfunction-related TR linked to ~268% higher all-cause mortality risk versus atrial TR.
Why the study?
Significant tricuspid regurgitation encompasses diverse etiologies, complicating the understanding of disease progression and prognostic factors, prompting an assessment of mortality by etiology and other predictive factors.
Cohort (n=757)
Yes
In patients with significant tricuspid regurgitation, all etiological groups (organic, left-sided valvulopathy, ventricular dysfunction, and pulmonary hypertension) exhibit a significantly higher mortality risk compared to atrial TR.
Answers are grounded in this paper and cite their sources.
May refine TR prognosis by etiology; leaves open whether targeted interventions alter outcomes.
BACKGROUND: Significant tricuspid regurgitation (TR) encompasses a wide range of etiologies, complicating a comprehensive understanding of disease progression and prognostic factors. This study aimed to assess mortality associated with significant TR, focusing on the role of valvular disease etiology and other predictive factors. METHODS: This is a retrospective, multicenter, cohort observational study, including all consecutive patients with moderate-to-severe or greater TR. The patients were classified into five etiological groups: organic TR, TR secondary to left valvulopathy, TR secondary to left or right ventricular dysfunction, TR secondary to pulmonary hypertension, and atrial TR. The long-term mortality was assessed (median follow-up: 39.8 months). RESULTS: 757 patients were included. The overall mortality incidence rate was 162.5 deaths per 1000 patient-years. Compared to atrial TR, all other etiologies presented a higher mortality risk: organic TR adjusted hazard ratio (aHR) = 2.344 (95% confidence interval [CI]: 1.138-4.829), left valvulopathy-related TR aHR = 1.901 (95% CI: 1.011-3.574), ventricular dysfunction-related TR aHR = 3.683 (95% CI: 1.627-8.338), and pulmonary hypertension-related TR aHR = 2.446 (95% CI: 1.215-4.927). In addition to known factors, male sex was associated with a higher mortality risk (aHR = 1.608, 1.175-2.201), while beta-blocker use was linked to a lower risk (aHR = 0.674, 0.502-0.904). CONCLUSIONS: In a large cohort of patients with significant TR, and after adjusting for clinical and echocardiographic variables, all etiological groups exhibited a higher mortality risk compared to atrial TR. Additionally, male patients with TR had a higher mortality risk, while beta-blocker therapy emerged as a protective factor.
No takes yet. Share an insight, caveat, or question.
Rodríguez‐Capitán et al. (2025) conducted a cohort in Significant tricuspid regurgitation (n=757). Ventricular dysfunction-related tricuspid regurgitation vs. Atrial tricuspid regurgitation was evaluated on All-cause mortality (aHR 3.683, 95% CI 1.627-8.338, p=0.002). Compared to atrial tricuspid regurgitation, ventricular dysfunction-related tricuspid regurgitation was associated with a significantly higher risk of all-cause mortality (aHR 3.683).
Synapse has enriched 10 related papers. Consider them for comparative context: